Comprehensive Overview of Interstitial Lung Diseases: A Guide for Medical Professionals
OthersPage Navigation
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary interstitium. This article provides a comprehensive overview of these complex diseases.
Etiology and Classification
ILDs can be idiopathic or associated with systemic diseases, environmental exposures, or medications. Idiopathic pulmonary fibrosis (IPF) is the most common ILD and is characterized by progressive fibrosis without a known cause. Other ILDs include sarcoidosis, hypersensitivity pneumonitis, and connective tissue disease-associated ILDs.
Clinical Presentation and Diagnosis
Patients typically present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and clubbing. High-resolution computed tomography (HRCT) is crucial for diagnosis. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management
Management strategies depend on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib can slow disease progression. In cases of ILD associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation may be considered in advanced cases.
Prognosis
The prognosis varies widely, depending on the specific type of ILD. IPF typically has a poor prognosis with a median survival of 2-3 years from diagnosis. On the other hand, ILDs associated with connective tissue diseases often have a more favorable prognosis.
In conclusion, ILDs are a diverse group of diseases with varying etiologies, clinical presentations, and prognoses. A thorough understanding of these diseases is essential for their effective management.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge